Your browser doesn't support javascript.
loading
SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection.
Hoyois, A; Gulkilik, C; Mekkaoui, L; Dahma, H; Wambacq, V; Minsart, C; Rosewick, N; Liefferinckx, C; Amininejad, L; Van Gossum, A; Cremer, A; Vandenberg, O; Franchimont, D.
Afiliación
  • Hoyois A; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Gulkilik C; Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
  • Mekkaoui L; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Dahma H; Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles, Brussels, Belgium.
  • Wambacq V; Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles, Brussels, Belgium.
  • Minsart C; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Rosewick N; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Liefferinckx C; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
  • Amininejad L; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Van Gossum A; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Cremer A; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Vandenberg O; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, HUB Hôpital Erasme, Université Libre de Bruxelles, Brussels Belgium.
  • Franchimont D; Innovation and Business Development Unit, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Acta Gastroenterol Belg ; 87(2): 263-273, 2024.
Article en En | MEDLINE | ID: mdl-39210758
ABSTRACT

Background:

Previous history of COVID-19 infection is a natural booster of the vaccine response in the general population. The response to COVID-19 vaccines is lessened in Inflammatory Bowel Disease patients on selected class of immunosuppressive treatments.

Aims:

The study was to assess anti-SARS-CoV-2 spike-specific IgG antibody response in Inflammatory Bowel Disease patients with a history of COVID-19 infection. Patients and

methods:

This single-center prospective study involved 504 Inflammatory Bowel Disease patients. Demographic data and clinical data were gathered through questionnaires and patient charts. Anti-SARS-CoV-2 spike-specific and antinucleocapsid antibody levels were measured at T1, T2 (after the 2-dose series), and T3 or T4 (booster vaccine).

Results:

This study included 504 Inflammatory Bowel Disease patients, and 234 completed one year follow-up with blood tests. Positive anti-nucleocapsid serology or history of COVID-19 infection was significantly associated with increased median anti- SARS-CoV-2 spike-specific IgG titers after the 2-dose series (1930 BAU/mL vs. 521 BAU/mL p < 0.0001) and the booster vaccine (4390 BAU/mL vs. 2160 BAU/mL, p = 0.0156). Multivariate analysis showed that higher anti-SARS-CoV-2 spike-specific IgG levels were independently associated with anti-nucleocapsid antibodies at T2 (OR=2.23, p < 0.0001) and T3 (OR=1.72, p = 0.00011). Immunosuppressive treatments did not impact the antibody response or levels in patients with a history of COVID-19 infection or positive anti-nucleocapsid serology.

Conclusions:

In Inflammatory Bowel Disease, prior COVID-19 infection or positive anti-nucleocapsid serology leads to increased anti-SARS-CoV-2 spike-specific IgG levels after vaccination, regardless of immunosuppressive treatments. This emphasizes the significance of accounting for previous infection in vaccination approaches.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulina G / Enfermedades Inflamatorias del Intestino / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Gastroenterol Belg Año: 2024 Tipo del documento: Article Pais de publicación: Bélgica
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulina G / Enfermedades Inflamatorias del Intestino / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Gastroenterol Belg Año: 2024 Tipo del documento: Article Pais de publicación: Bélgica